Friday, 16 October 2026European Markets

58% of EU accounts payable staff skip fraud checks under time pressure

Over half of accounts payable professionals in EU-regulated companies admit to occasionally bypassing verification steps due to time constraints, creating systemic fraud vulnerabilities. AI-driven automated verification systems can eliminate these shortcuts while matching or exceeding manual processing speeds. The gap between compliance requirements and operational reality exposes companies to both financial losses and regulatory penalties.

58% of EU accounts payable staff skip fraud checks under time pressure
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

58% of accounts payable professionals skip verification steps at least occasionally due to time pressure, according to PYMNTS research examining payment processing vulnerabilities.

This practice creates systemic fraud exposure in EU-regulated companies, where MiFID II, AMLD6, and corporate governance directives mandate robust internal controls. Manual verification processes force finance teams to choose between speed and compliance.

AI-driven automated verification eliminates this trade-off. Pelican Canada Inc., with over 25 years in payment processing and financial crime compliance, has demonstrated that AI systems can maintain 100% verification coverage while reducing processing time.

"In global money movement, a production-ready AI strategy relies on the quality of data," said Peter Cavicchia, highlighting the technical foundation required for automated controls.

EU companies face dual exposure from verification shortcuts. Financial losses from undetected fraud compound with regulatory penalties for inadequate controls. The European Banking Authority has increased scrutiny of payment processing controls following recent fraud cases.

AI automation addresses three critical points: invoice validation against purchase orders, vendor verification against approved lists, and payment authorization workflows. Traditional manual processes struggle with volume during month-end cycles, creating predictable vulnerability windows.

The compliance implications extend beyond immediate fraud prevention. Audit committees must now assess whether manual AP processes can credibly meet regulatory standards. External auditors are questioning the reliability of controls that depend on 100% human compliance under time pressure.

Implementation requires structured data feeds and integration with existing ERP systems. Companies with clean vendor master data and standardized invoice formats see faster deployment. The technology exists; adoption depends on finance leadership recognizing that current manual processes create unacceptable risk.

For EU-regulated entities, the question is no longer whether to automate AP verification, but how quickly they can implement systems that eliminate the human choice between speed and compliance.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com